Guardian Wealth Advisors LLC NC Invests $207,000 in Novo Nordisk A/S (NYSE:NVO)

Guardian Wealth Advisors LLC NC bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,404 shares of the company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Center for Financial Planning Inc. lifted its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $39,000. Finally, Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. BMO Capital Markets reiterated a “market perform” rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating on the stock. Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Finally, Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Stock Up 1.4%

Shares of Novo Nordisk A/S stock opened at $65.75 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $69.21 and its 200-day simple moving average is $85.83. The stock has a market capitalization of $295.06 billion, a price-to-earnings ratio of 19.98, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $79.17 billion. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.